WASHINGTON, April 26, 2013 /PRNewswire/ -- PharMEDium is encouraged by the progress made today by the twelve bipartisan Members of the Senate Health, Education, Labor, and Pensions (HELP) Committee toward assuring the highest level of safety possible for patients who receive sterile compounded preparations. The Senate HELP Committee has produced a detailed and thoughtful Bill which goes a long way toward addressing the complicated but crucial question of how to improve regulatory oversight of this vital sector of the pharmacy industry.
PharMEDium, the nation's leading provider of sterile admixture preparations for hospitals throughout the country, supports the proposed new category of "compounding manufacturer," federal oversight and inspections of these facilities to applicable cGMP standards. While we recognize this is the beginning of a lengthy legislative process, we encourage those in our industry to join us in supporting these efforts to achieve and maintain the highest quality of safety for users of sterile preparations. PharMEDium has long advocated for increased FDA authority and oversight of the sterile compounding process and looks forward to working with the Committee and Members of Congress on the further development and passage of this important legislation.
Who we are: PharMEDium is one of the nation's leading providers of hospital pharmacy-outsourced, sterile admixture services with centers in four states and thousands of acute care hospital customers nationwide. Our qualified personnel and state-of-the-art centers are registered with the FDA, licensed by states as compounding pharmacies and governed by our own rigorous quality standards. We begin the compounding process with sterile FDA-approved drugs from FDA-approved drug manufacturers. It is our mission to be the preeminent provider of choice for hospital customers and to attain the highest degree of integrity in the compounding of sterile preparations.Contact:
Bob Szafranski Bob.Szafranski@edelman.com312-863-9135 (mobile)312-240-2687 (work)
Copyright©2012 PR Newswire.
All rights reserved